Quick Comparison
| Factor | BPC-157 | TB-500 |
|---|---|---|
| Origin | Fragment of a protective protein found in human gastric juice | Related to Thymosin Beta-4, a naturally occurring actin-regulating protein |
| Primary proposed mechanism | Growth factor and angiogenesis pathways (VEGFR2), nitric oxide modulation | Actin binding, which governs cell migration and movement |
| Community-discussed scope | Often framed around localized tissue and gut-related healing | Often framed around systemic tissue repair and cell migration across a wider area |
| Human clinical trials | None identified | None for the TB-500 fragment itself; the full-length Thymosin Beta-4 molecule has limited early trial history for wound healing and dry eye |
| 2026 FDA 503A status | PCAC recommended, July 2026 (nonbinding) | PCAC recommended, July 2026 (nonbinding) |
What BPC-157 Is
BPC-157 ("Body Protection Compound-157") is a synthetic peptide based on a fragment of a protein naturally found in human gastric juice. The preclinical research base is built mostly around gut lining healing, tendon and ligament repair, and general anti-inflammatory effects, with proposed mechanisms centered on growth factor pathways involved in angiogenesis and modulation of the nitric oxide system. See BPC-157 Human Studies for the full evidence picture, including the current absence of peer-reviewed human trials.
What TB-500 Is
TB-500 is a synthetic peptide related to Thymosin Beta-4, a naturally occurring protein that regulates actin, the structural protein cells use to move. That mechanism is why TB-500 gets discussed in terms of cell migration and systemic tissue repair rather than a purely localized effect. The full-length Thymosin Beta-4 molecule has some limited early human trial history for wound healing and dry eye, but the TB-500 fragment sold as a research chemical has no dedicated human trials of its own. See TB-500 Human Studies for the full breakdown of that distinction.
The Key Difference: Local vs Systemic
The clearest practical distinction between the two comes down to scope. BPC-157's mechanism is more associated with localized healing at and around an injury site, along with a specific gut-healing angle tied to its origin. TB-500's actin-binding mechanism is discussed more in terms of cell migration across a broader area, which is part of why it's associated with flexibility and systemic recovery rather than one specific site. Neither mechanism has been directly compared to the other in a controlled human trial, so this distinction comes from each compound's separate preclinical research, not a head-to-head study.
Why this matters: because the two mechanisms are proposed to work differently rather than duplicating each other, they're generally discussed as complementary rather than as alternatives to pick between. That's the entire logic behind stacking them.
Why They're Usually Stacked Instead of Compared
The combination of BPC-157 and TB-500 has its own community nickname, the "Wolverine stack," referencing the X-Men character's rapid-healing ability. See Wolverine Peptide Stack: What Is It? for where that name comes from, and the full TB-500 and BPC-157 stack guide for actual dosing and cycling information. No published research has tested the combination directly, so the rationale for stacking them rests on their separate, non-overlapping mechanisms rather than a demonstrated combined effect.
Regulatory Status
Neither BPC-157 nor TB-500 is an FDA-approved drug. Both were among the seven peptides the FDA's Pharmacy Compounding Advisory Committee reviewed in July 2026, and both were recommended for a possible future compounding pathway under Section 503A. That recommendation is nonbinding, and neither compound is on the 503A Bulks List as of this writing. See What Changed With BPC-157, TB-500 and MOTS-c in 2026? for the full story, and the FDA Peptide Status Tracker for current status.
Bloodwork to Track
Neither compound has a single standard bloodwork marker tied specifically to it. A general safety baseline, a comprehensive metabolic panel and CBC, is a reasonable starting point for either or both. See the peptide bloodwork guide for what a baseline panel typically includes.
Where to buy
Compare prescription compounding and research-grade sources for each:
Related Reading
For the core TB-500 compound reference, see TB-500: Dosing, Mechanism and Regulatory Status. For the full dosing and cycling protocol for combining them, see TB-500 & BPC-157 Stack: Recovery Protocol. For each compound's individual human evidence picture, see BPC-157 Human Studies and TB-500 Human Studies. BioStackIQ's Rate My Stack and Build Protocol can help you think through where either or both fit into a broader stack.
Frequently Asked Questions
Is BPC-157 or TB-500 better?
Neither is straightforwardly "better," because they work through different mechanisms and are typically discussed for somewhat different purposes. BPC-157 is more associated with localized, gut-and-tissue-specific healing, while TB-500 is more associated with cell migration and systemic tissue repair. That difference is exactly why they're commonly stacked together rather than compared as substitutes.
What's the main mechanism difference between BPC-157 and TB-500?
BPC-157 is derived from a protective protein fragment found in human gastric juice and is studied mainly around growth factor and angiogenesis pathways. TB-500 is related to Thymosin Beta-4, a naturally occurring protein involved in actin regulation, the cellular machinery that controls cell movement, which is why it's discussed in terms of cell migration and systemic tissue repair rather than a localized effect.
Does either BPC-157 or TB-500 have human clinical trial data?
No peer-reviewed human trials exist for BPC-157 itself. TB-500 as sold is a fragment of the full-length Thymosin Beta-4 protein, and while the full-length molecule has some limited early human trial history for wound healing and dry eye, the TB-500 fragment specifically has no dedicated human trials. Both compounds rely mainly on preclinical animal research and anecdotal human reports.
Why do people stack BPC-157 and TB-500 instead of using just one?
The rationale is that they act through different, non-overlapping mechanisms, so combining them is viewed as complementary rather than redundant. This nickname for the combination is the "Wolverine stack." No published research has tested the combination directly, so this reasoning is based on the two compounds' separate mechanisms, not a demonstrated combined effect.
What's the current regulatory status of BPC-157 and TB-500?
Neither is an FDA-approved drug. Both were reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026 and recommended for a future compounding pathway under Section 503A, but that recommendation is nonbinding and neither is on the 503A Bulks List as of this writing.